Top

Current Neurology and Neuroscience Reports

Published in:

01-05-2017 | Movement Disorders (S Fox, Section Editor)

Multiple System Atrophy - State of the Art

Authors: Brice Laurens, Sylvain Vergnet, Miguel Cuina Lopez, Alexandra Foubert-Samier, François Tison, Pierre-Olivier Fernagut, Wassilios G. Meissner

Published in: Current Neurology and Neuroscience Reports | Issue 5/2017

Abstract

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that is characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. Some symptomatic treatments are available while neuroprotection or disease-modification remain unmet treatment needs. The pathologic hallmark is the accumulation of aggregated alpha-synuclein (α-syn) in oligodendrocytes forming glial cytoplasmic inclusions, which qualifies MSA as synucleinopathy together with Parkinson’s disease and dementia with Lewy bodies. Despite progress in our understanding of the pathogenesis of MSA, the origin of α-syn aggregates in oligodendrocytes is still a matter of an ongoing debate. We critically review here studies published in the field over the past 5 years dealing with pathogenesis, genetics, clinical signs, biomarker for improving diagnostic accuracy, and treatment development.

Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.CrossRefPubMedPubMedCentral

Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, et al. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis. 2014;67:133–9.CrossRefPubMed

Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94(1/3):79–100.CrossRefPubMed

Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994;117(Pt 2):235–43.CrossRefPubMed

Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205–8.CrossRefPubMed

Salvesen L, Ullerup BH, Sunay FB, Brudek T, Lokkegaard A, Agander TK, et al. Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy—a stereological study. Neurobiol Dis. 2015;74:104–13.CrossRefPubMed

Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138(Pt 8):2293–309.CrossRefPubMedPubMedCentral

• Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62(6):964–70. SNCA gene expression was assessed in several brain regions in patients with MSA, PD and healthy controls. Highest expression was found in the cortex and lowest in the putamen, with no differences observed between groups. SNCA expression was similarly found in neurons and oligodendrocytes.CrossRefPubMedPubMedCentral

• May VE, Ettle B, Poehler AM, Nuber S, Ubhi K, Rockenstein E, et al. alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging. 2014;35(10):2357–68. Post-mortem study describing α-syn deposits in OPCs and an increased number of striatal OPCs in MSA patients.CrossRefPubMedPubMedCentral

10.

• Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, et al. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports. 2015;5(2):174–84. Comprehensive in-vitro characterization showing α-syn protein and its transcripts in oligodendrocytes generated from mouse and human embryonic stem cells, in induced pluripotent stem cells derived from fibroblasts of MSA patients and in oligodendrocytes of adult MSA brains.CrossRefPubMedPubMedCentral

11.

Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62(3):387–98.CrossRefPubMed

12.

Kisos H, Pukass K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS One. 2012;7(10), e46817.CrossRefPubMedPubMedCentral

13.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855–66.CrossRefPubMedPubMedCentral

14.

Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA. 2013;110(48):19555–60.CrossRefPubMedPubMedCentral

15.

Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308–17.CrossRefPubMedPubMedCentral

16.

Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340–4.CrossRefPubMed

17.

Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. Brain Pathol. 2013;23(3):263–73.CrossRefPubMed

18.

Song YJ, Lundvig DM, Huang Y, Gai WP, Blumbergs PC, Hojrup P, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol. 2007;171(4):1291–303.CrossRefPubMedPubMedCentral

19.

Ota K, Obayashi M, Ozaki K, Ichinose S, Kakita A, Tada M, et al. Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. Acta Neuropathol Commun. 2014;2:136.PubMedPubMedCentral

20.

Vieira BD, Radford RA, Chung RS, Guillemin GJ, Pountney DL. Neuroinflammation in multiple system atrophy: response to and cause of alpha-synuclein aggregation. Front Cell Neurosci. 2015;9:437.CrossRefPubMedPubMedCentral

21.

Radford R, Rcom-H'cheo-Gauthier A, Wong MB, Eaton ED, Quilty M, Blizzard C, et al. The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to alpha-synuclein inclusions. Mol Cell Neurosci. 2015;65:68–81.CrossRefPubMed

22.

Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012;16(6):1166–83.CrossRefPubMedPubMedCentral

23.

Pukass K, Goldbaum O, Richter-Landsberg C. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells. J Neurochem. 2015;135(1):194–205.CrossRefPubMed

24.

Bassil F, Canron MH, Vital A, Bezard E, Yazhou L, Greig NH, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain. 2017; doi:10.1093/brain/awx044.

25.

• Multiple-system atrophy research collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233–44. Description of a homozygous mutation and compound heterozygous mutations in the COQ2 gene in two multiplex families with MSA. Additional studies including cohorts from Asia have not confirmed or only partly replicated these findings.CrossRef

26.

Schottlaender LV, Houlden H, Multiple-System Atrophy Brain Bank C. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):81.PubMed

27.

Jeon BS, Farrer MJ, Bortnick SF, Korean Canadian Alliance on Parkinson's disease, related disease. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):80.CrossRefPubMed

28.

Sharma M, Wenning G, Kruger R. European multiple-system atrophy study, G. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):80–1.CrossRefPubMed

29.

Ogaki K, Fujioka S, Heckman MG, Rayaprolu S, Soto-Ortolaza AI, Labbe C, et al. Analysis of COQ2 gene in multiple system atrophy. Mol Neurodegener. 2014;9:44.CrossRefPubMedPubMedCentral

30.

Lin CH, Tan EK, Yang CC, Yi Z, Wu RM. COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese. Mov Disord. 2015;30(3):436–7.CrossRefPubMed

31.

Sun Z, Ohta Y, Yamashita T, Sato K, Takemoto M, Hishikawa N, et al. New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy. Neurol Genet. 2016;2(2), e54.CrossRefPubMedPubMedCentral

32.

Ronchi D, Di Biase E, Franco G, Melzi V, Del Sorbo F, Elia A, et al. Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging. 2016;45:213. e1-2.

33.

Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol. 2016;75(7):663–72.CrossRefPubMed

34.

Schottlaender LV, Bettencourt C, Kiely AP, Chalasani A, Neergheen V, Holton JL, et al. Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. PLoS One. 2016;11(2), e0149557.CrossRefPubMedPubMedCentral

35.

Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Durr A, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015;2(4):417–26.CrossRefPubMedPubMedCentral

36.

Sun Z, Jiang H, Jiao B, Hou X, Shen L, Xia K, et al. C9orf72 hexanucleotide expansion analysis in Chinese patients with multiple system atrophy. Parkinsonism Relat Disord. 2015;21(7):811–2.CrossRefPubMed

37.

Chelban V, Manole A, Pihlstrom L, Schottlaender L, Efthymiou S, Connor EO, et al. Analysis of the prion protein gene in multiple system atrophy. Neurobiol Aging. 2017;49:216 e15–e18.CrossRef

38.

Scholz SW, Majounie E, Revesz T, Holton JL, Okun MS, Houlden H, et al. Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiol Aging. 2015;36(2):1223 e1–2.CrossRef

39.

Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B, et al. C9ORF72 repeat expansions in Chinese patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna). 2016.

40.

• Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, et al. A genome-wide association study in multiple system atrophy. Neurology. 2016;87(15):1591–8. Largest GWAS including 918 MSA patients. No association was found for any of the assessed genes, which may partly be explained by the still relatively low number of assessed cases. Several loci were identified for future follow-up in larger sample series including the genes FBXO47, ELOVL7, EDN1 and MAPT.

41.

Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, et al. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry. 2016;87(5):554–61.CrossRefPubMed

42.

• Giannini G, Calandra-Buonaura G, Mastrolilli F, Righini M, Bacchi-Reggiani ML, Cecere A, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology. 2016;87(13):1375–83. Large retrospective series of 136 MSA patients among whom 42 presented with stridor. Patients with stridor onset within the first three years showed shorter survival. Thirty-one patients were treated with tracheotomy or continous positive airway pressure (CPAP). Treatment had a positive effect on survival with tracheotomy being more effective than CPAP.CrossRefPubMed

43.

Flabeau O, Ghorayeb I, Perez P, Maillard A, Taillard J, Philip P, et al. Impact of sleep apnea syndrome on survival in patients with multiple system atrophy. Parkinsonism Relat Disord. 2017;35:92–95.

44.

Wang Y, Shao WB, Gao L, Lu J, Gu H, Sun LH, et al. Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy—comparison with normal elderly. PLoS One. 2014;9(12), e116123.CrossRefPubMedPubMedCentral

45.

Teive HA, Arruda WO, Moro A, Moscovich M, Munhoz RP. Differential diagnosis of sporadic adult-onset ataxia: the role of REM sleep behavior disorder. Parkinsonism Relat Disord. 2015;21(6):640–3.CrossRefPubMed

46.

Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012;11(4):361–8.CrossRefPubMed

47.

Kass-Iliyya L, Kobylecki C, McDonald KR, Gerhard A, Silverdale MA. Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease. Brain Behav. 2015;5(5), e00320.CrossRefPubMedPubMedCentral

48.

Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord. 2014;29(7):857–67.CrossRefPubMedPubMedCentral

49.

• Auzou N, Dujardin K, Biundo R, Foubert-Samier A, Barth C, Duval F, et al. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. Parkinsonism Relat Disord. 2015;21(10):1273–7. This study applied PDD procedures in 111 MSA patients and found that the short screening test may be useful for the diagnosis of MSA dementia, keeping in mind that cognitive impairment is a non-supporting feature of current diagnosis criteria for MSA.CrossRefPubMed

50.

Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85(5):404–12.CrossRefPubMedPubMedCentral

51.

Asi YT, Ling H, Ahmed Z, Lees AJ, Revesz T, Holton JL. Neuropathological features of multiple system atrophy with cognitive impairment. Mov Disord. 2014;29(7):884–8.CrossRefPubMed

52.

Lee YC, Liu CS, Wu HM, Wang PS, Chang MH, Soong BW. The “hot cross bun” sign in the patients with spinocerebellar ataxia. Eur J Neurol. 2009;16(4):513–6.CrossRefPubMed

53.

Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology. 2002;59(8):1265–7.CrossRefPubMed

54.

Deguchi K, Ikeda K, Kume K, Takata T, Kokudo Y, Kamada M, et al. Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy. J Neurol. 2015;262(6):1433–9.CrossRefPubMed

55.

• Scherfler C, Gobel G, Muller C, Nocker M, Wenning GK, Schocke M, et al. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology. 2016;86(13):1242–9. MRI study performing automated volume measures of 22 subcortical regions in patients with MSA, PD and PSP. Midbrain, putamen, and cerebellum were the most useful regions to construct a prediction model. This model was tested in a validation set in which all MSA patients were correctly classified.CrossRefPubMed

56.

Barbagallo G, Sierra-Pena M, Nemmi F, Traon AP, Meissner WG, Rascol O, et al. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord. 2016;31(3):325–34.CrossRefPubMed

57.

Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord. 2010;25(11):1744–7.CrossRefPubMed

58.

Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis. 2015;80:29–41.CrossRefPubMed

59.

Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol. 2014;128(1):99–109.CrossRefPubMedPubMedCentral

60.

Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology. 2014;82(15):1362–9.CrossRefPubMed

61.

• Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain. 2015;138(Pt 8):2310–21. Description of α-syn deposits in skin sympathetic nerve fibers around sweat glands in PD but not in MSA patients. The study also reported decreased density of the fibers innervating autonomic skin structures in PD but not in MSA.CrossRefPubMed

62.

• Doppler K, Weis J, Karl K, Ebert S, Ebentheuer J, Trenkwalder C, et al. Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. Mov Disord. 2015;30(12):1688–92. Description of distinct patterns of α-syn deposition in the skin of patients with MSA (mainly somatosensory fibers of the subepidermal plexus) and PD (prominent in autonomic fibers).CrossRefPubMed

63.

Haga R, Sugimoto K, Nishijima H, Miki Y, Suzuki C, Wakabayashi K, et al. Clinical utility of skin biopsy in differentiating between parkinson's disease and multiple system atrophy. Parkinsons Dis. 2015;2015:167038.PubMedPubMedCentral

64.

Provitera V, Nolano M, Caporaso G, Stancanelli A, Manganelli F, Iodice R, et al. Post-ganglionic sudomotor denervation in patients with multiple system atrophy. Neurology. 2014;82(24):2223–9.CrossRefPubMed

65.

Corbille AG, Letournel F, Kordower JH, Lee J, Shanes E, Neunlist M, et al. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016;4:35.CrossRefPubMedPubMedCentral

66.

Pouclet H, Lebouvier T, Coron E, Rouaud T, Flamant M, Toulgoat F, et al. Analysis of colonic alpha-synuclein pathology in multiple system atrophy. Parkinsonism Relat Disord. 2012;18(7):893–5.CrossRefPubMed

67.

Chung SJ, Kim J, Lee HJ, Ryu HS, Kim K, Lee JH, et al. Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker. Mov Disord. 2016;31(2):241–9.CrossRefPubMed

68.

Valera E, Monzio Compagnoni G, Masliah E. Review: novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol. 2016;42(1):95–106.CrossRefPubMedPubMedCentral

69.

Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, et al. Targeting alpha-synuclein: therapeutic options. Mov Disord. 2016;31(6):882–8.CrossRefPubMed

70.

Sturm E, Fellner L, Krismer F, Poewe W, Wenning GK, Stefanova N. Neuroprotection by epigenetic modulation in a transgenic model of multiple system atrophy. Neurotherapeutics. 2016;13(4):871–879.

71.

• Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015;10:10. Proof of concept showing beneficial effects of active vaccination with AFF1 (corresponds to Affitope PD01A in human trials) in transgenic MSA mice on accumulation of α-syn, demyelination, and neurodegeneration.CrossRefPubMedPubMedCentral

72.

• Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci USA. 2016;113(34):9593–8. Proof of concept of the ability of the caspase-1 inhibitor prodrug VX-765 to mitigate α-syn pathology and to mediate neuroprotection in transgenic MSA mice. VX-765 prevented motor deficits in PLP-SYN, reduced the levels of truncated α-syn and showed neuroprotective effects by preserving dopamine neurons in the substantia nigra.CrossRefPubMedPubMedCentral

73.

Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. 2015;10:48.CrossRefPubMedPubMedCentral

74.

Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008;210(2):421–7.CrossRefPubMed

75.

Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol. 2012;234(2):405–16.CrossRefPubMedPubMedCentral

76.

Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport. 2008;19(13):1271–6.CrossRefPubMedPubMedCentral

77.

Kaindlstorfer C, Sommer P, Georgievska B, Mather RJ, Kugler AR, Poewe W, et al. Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications. Neurotox Res. 2015;28(3):185–94.CrossRefPubMedPubMedCentral

78.

Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res. 2012;21(4):393–404.CrossRefPubMed

79.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–7.CrossRefPubMed

80.

Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, Phase 3 trial. Neurology. 2014;83(4):328–35.CrossRefPubMedPubMedCentral

81.

Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(3):268–75.CrossRefPubMedPubMedCentral

82.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomized, placebo-controlled trial. Lancet Neurol. 2015;14(2):145–52.CrossRefPubMed

83.

Rascol O. French MSA-Fluoxetine Study Group. Preliminary results of the French MSA-fluoxetine study. Eur J Neurol. 2012;19 Suppl 1:262.

84.

Tada M, Kakita A, Toyoshima Y, Onodera O, Ozawa T, Morita T, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain. 2009;132(Pt 7):1810–9.CrossRefPubMed

85.

Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72(1):32–40.CrossRefPubMed

86.

Sacca F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol. 2013;260(2):458–61.CrossRefPubMed

Title: Multiple System Atrophy - State of the Art
Authors: Brice Laurens
Sylvain Vergnet
Miguel Cuina Lopez
Alexandra Foubert-Samier
François Tison
Pierre-Olivier Fernagut
Wassilios G. Meissner
Publication date: 01-05-2017
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 5/2017
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-017-0751-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multiple System Atrophy - State of the Art

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Reflections on Ethics and Humanity in Pediatric Neurology: the Value of Recognizing Ethical Issues in Common Clinical Practice

A Novel Way to Measure and Predict Development: A Heuristic Approach to Facilitate the Early Detection of Neurodevelopmental Disorders

Sleep Disordered Breathing in Duchenne Muscular Dystrophy

The Spectrum of Vestibular and Ocular Motor Abnormalities in Thiamine Deficiency

Cognitive and Behavioral Interventions in Epilepsy

Genetic Testing in Pediatric Epilepsy